Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

CDL301 Cardiovascular Pharmacology Refesher > Lecture 14 Haemostasis and Thrombostasis > Flashcards

Lecture 14 Haemostasis and Thrombostasis Flashcards

1
Q

What are the sub-classifications of bleeding

A

Primary and secondary haemostasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the sub-classifications of clotting

A

Arterial and venous thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What three fractions are isolated from fresh whole blood following donation

A

Red blood cells platelets and plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How long can red blood cells be kept and used for after donation

A

35 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How long can platelets be kept and used for after donation

A

5-7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How long can plasma be kept and used for after donation

A

Can be frozen and stored for quite some time before use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How can fresh frozen plasma be further divided

A

Plasma can be separated into the individual clotting factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the first response to bleeding

A

Localised vasoconstriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the two components to the clotting system

A

Primary haemostasis – platelet activation and adhesion. Secondary haemostasis – activation of the coagulation cascade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the role of the coagulation cascade

A

To produce fibrin that fixes the cells together

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the two causes of platelet bleeding disorders

A

Reduced platelet numbers (thrombocytopenia) or impaired platelet function that is either inherited or acquired

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How are patients with platelet bleeding disorders treated

A

Platelet transfusions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How to platelets bind to collagen in the endothelium during clotting

A

Via the binding of von Willebrand factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the inheritance pattern of von Willebrand disease

A

Autosomal dominant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Von Willebrand disease is the most common inherited bleeding disorder with as many as 10% of the population having reduced vWF levels T or F

A

F – whilst it is the most common inherited bleeding disorder its 1% of the population who have reduced vWF levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Von Willebrand disease is a milder bleeding disorder to haemophilia T or F

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the main symptoms of von Willebrand disease

A

Bruising cuts mennohagia epistaxis (nose bleeds) and bleeding of the gums

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the two approaches in the treatment of von Willebrand disease

A

Desmopressin to stimulate endothelial cell degranulation of the Weibel-Palade bodies that contain vWF. Alternatively intermediate purity/plasma-derived factor VIII is given which contains vWF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the name of the granules that contain vWF in the endothelial cells

A

Weibel-Palade bodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What factor is activated first in the imitation of secondary haemostasis

A

Tissue factor or clotting factor VIIa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the main activator of the coagulation cascade in humans

A

Clotting factor VIIa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How is factor VIIa activated during vessel injury

A

Injury to the vessel exposes FVIIa which is underneath the vessel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are the two effects of activating factor VIIa

A

FVIIa both directly and indirectly leads to the conversion of factor X to factor Xa. It directly stimulates this conversion but also acts via triggering the conversion of factor IX to IXa which then stimulates factor X conversion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Which pathway of factor Xa production is more efficient

A

The indirect pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What is the role of factor Xa in the coagulation cascade
Factor Xa activates the conversion of factor II to factor IIa. Factor IIa is also known as thrombin and is the enzyme responsible for catalysing the conversion of fibrinogen to fibrin
26
Below is an outline of the coagulation cascade fill in the missing clotting factors
See completed diagram below
27
What is the inheritance pattern of haemophilia A and B
X-linked
28
Haemophilia A and B have distinct clinical features T or F
F – they have identical clinical features
29
Which clotting factor is deficient in haemophilia A
FVIII
30
Which clotting factor is deficient in haemophilia V
FIX
31
Where is bleeding often seen in haemophilia
Joints and muscles
32
How is haemophilia A severity classified
Based on the levels of FVIII present in the blood normal levels are around 50-150%.
33
Outline the different severities of haemophilia A and how this relates to the incidence of bleeding
Severe Haemophilia A – \<1% FVIII (20-40 times a year spontaneous bleeding). Moderate Haemophilia A – 1-5% FVIII (1-2 times a year spontaneous bleeding). Mild Haemophilia A – \>5% FVIII (no spontaneous bleeding)
34
Other than bleeding what are the symptoms of haemophilia
Wasted quadriceps due to impaired mobility haemarthrosis causing severe joint damage due to degradation of cartilage
35
Which is the only clotting factor for which there is not a concentrate for
Factor V because it is rarely deficient in patients
36
What is the other name for factor I
Fibrinogen
37
What is the other name for factor II
Prothrombin
38
Which clotting factors have recombinant concentrates
VII VIII IX and XIII
39
Outline how primary and secondary haemostatic disorders are treated
Primary haemostatic disorders such as von Willebrand disease are treated with platelet transfusions desmopressin or vWF concentrate. Secondary haemostatic disorders such as haemophilia are treated with the specific clotting factors required
40
Give an example of a primary haemostatic disorder
Von Willebrand Disease
41
Give an example of a secondary haemostatic disorder
Haemophilia
42
What is meant by thrombosis
Inappropriate blood coagulation
43
When is coagulation important
Appropriate coagulation occurs when blood escapes from the vessel
44
How do arterial and venous thromboses differ
Arterial thromboses occur in high pressure environments and are platelet rich. These often cause myocardial infarctions and thrombotic strokes. Meanwhile venous thromboses occur in low pressure systems and are fibrin rich. These usually case deep vein thromboses and pulmonary embolisms
45
How are arterial and venous thromboses treated differently
Arterial thromboses are treated with anti-platelet drugs whereas venous thromboses are treated with anti-coagulant drugs
46
List examples of antiplatelet drugs
Aspirin clopidogrel prasugrel ticagrelor cangrelor abciximab eptifibatide and tirofiban
47
What are the three types of delivery of anticoagulant drugs
Intravenous subcutaneous and oral
48
Which anticoagulants are administered intravenously
Unfractionated heparin
49
Which anticoagulants are administered subcutaneously
Low molecular weight heparin (Fragmin)
50
Which anticoagulants are administered orally
Warfarin dabigatran rivaroxaban apixaban and edoxaban
51
What class of drugs to warfarin and acenocoumarol belong to
Vitamin K antagonists
52
What is the mechanism of action of heparin in thrombosis
Heparin binds to and activates the naturally occurring anticoagulant anti-thrombin. Antithrombin inhibits FXIa FXa FIXa and FIIa (thrombin) which in turn prevents fibrin formation and subsequent clot formation
53
What kind of molecules is heparin
Glycosaminoglycan
54
Heparin is known as an indirect thrombin inhibitor T or F
T
55
What is the APTT test
The activated partial thromboplastin time is a test used to monitor the response of a patient to heparin by characterising blood coagulation
56
How is heparin administered
By continuous infusion
57
What is the downside to using heparin as an anticoagulant
Heparin given to patients consists of a variation of heparin chain lengths from 4kDa to 35kDa. This means that coagulation is less reproducible and controllable in patients
58
What are the main benefits of low molecular weight heparin over standard unfractionated heparin
Low molecular weight heparin is only the 7kDa heparin molecule. There is thus much less variation in dose it can be given subcutaneously once a day and it is renally excreted
59
Low molecular weight heparin can only be used for treatment of venous thrombosis T or F
F – it can be used for prophylaxis as well
60
What is the benefit of warfarin in terms of its delivery
Warfarin can be delivered orally and is completely and rapidly absorbed
61
What is the overall effect of warfarin on clotting factors
Warfarin inhibits the production of factors II VII IX X (vitamin K dependent factors)
62
Why is it that warfarin has a slow on and slow off effect
This is due to the long half-life of the clotting factors. You have to wait for the already synthesised clotting factors to be degraded
63
What are the side effects of warfarin
Bleeding embryopathy
64
What variable is measured to monitor warfarin effectiveness
International normalised ratio which is essentially a measure of how quickly a patients’ blood clots compared to control
65
What is meant by a INR of 2.0
The patients’ blood will take twice as long to clot as normal
66
What is the INR value of a healthy patient
1
67
What is the desired INR for DVT/PE
2.0 – 3.0
68
What determines how frequently a patient on warfarin is monitored
The frequency of monitoring depends on the stability of the patient’s INR. This varies with the vitamin K levels and hence monitoring can be once per week up to once every 8 weeks
69
The INR of a warfarinised patient must be measured before surgery T or F
T
70
What is the average dose of warfarin required
5mg
71
Outline the vitamin K cycle and how warfarin interacts with it
The liver synthesises factors II VII IX X PC PS and other clotting factors but in order to become functional these factors need to be carboxylated. γ-glutamyl carboxylase (GGCX) is the enzyme that mediates the carboxylation of the clotting factors however GGCX requires vitamin K for its function. Once vitamin K is used by GGCX during carboxylation it becomes oxidised. Vitamin K epoxide Reductase Complex subunit 1 (VKORC1) converts oxidised vitamin K to its reduced form which can then be used by GGCX. Warfarin inhibits VKOR leading to a reduction in reduced vitamin K. This leads to an accumulation of oxidised vitamin K which cannot be used in the carboxylation of clotting factors and hence less active clotting factors are produced
72
Explain how SNPs in VKORC1 can change a patient’s response to warfarin
A single nucleotide polymorphism in VKORC1 (1639G\>A) results in a decreased activity of the genes’ promoter and subsequently a 44% decreased expression level. This renders patients more sensitive to warfarin as they already have decreased levels of reduced vitamin K and decreased levels of active clotting factors
73
What is the role of CYP2C9 in warfarin activity
CYP2C9 is the enzyme responsible for metabolising warfarin to its inactive metabolites
74
Explain how SNPs in CYP2C9 can change a patient’s response to warfarin
SNPs in CYP2C9 change its activity in metabolising warfarin. The main SNPs \*2 and \*3 are reduction-of function (ROF) variants that decrease the ability of the enzyme to metabolise warfarin by 30-40% and 80-90% respectively. This hence renders the patient more sensitive to the drug and with increased plasma concentrations.
75
How can warfarin administration be personalised to individual patients
Patients can have the VKORC1 and CYP2C9 genes genotyped to determine their ability to respond to and metabolise warfarin. Their genotype information can then be fed into an algorithm which can calculate the dose of warfarin that is appropriate for that patient
76
What is the major limitation in personalising warfarin doses
Genotyping patients prior to warfarin administration takes days and therefore isn’t suitable in treating acute bleeding
77
What are the main benefits of direct oral anticoagulants
Orally administered require no monitoring have standard dosing don’t interact with alcohol or food and similarly donkt interact with many other drugs
78
What are the downsides to DOACs
They have a short half-life and hence are required daily but are considerably more expensive than warfarin
79
Which DOACs are licenced in the UK
Dabigatran rivaroxaban apixaban and edoxaban
80
Which DOACs inhibit factor IIa/thrombin
Dabigatran
81
Which DOACs inhibit factor Xa
Rivaroxaban edoxaban and apixaban
82
Which thrombotic condititions are DOACs licenced for
All are licenced in the treatment of atrial fibrillation DVT and PE. All apart from edoxaban are licenced for thromboprophylaxis
83
What is the main concern when developing a novel anti-coagulant drug
The ability to reverse their effects
84
How can the effects of dabigatran be reversed
Using the humanised monoclonal antibody against the drug. This is now licenced for the reversal of dabigatran anticoagulation
85
How can the effects of rivaroxaban apixaban and edoxaban be reversed
Andexanet is a recombinant modified inactive factor Xa molecule that binds the drug in the circulation and prevents its action on endogenous factor Xa

CDL301 Cardiovascular Pharmacology Refesher (17 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions